Profile data is unavailable for this security.
About the company
Parenteral Drugs (India) Limited is engaged in the manufacturing of pharmaceutical products. It also manufactures intravenous (IV) infusion, inhalation, and veterinary infusion. It offers products in various categories, including IV fluids, oncology, anesthesia and exports. Its IV Fluids include Carbohydrated and Electrolytes, such as Dextrose IP 5%, 10%, 20%, Dextrose IP 25% , and Ringer Lactate IP; Diuretics, such as Mannitol 10%, 20% and Manidex (Mannitol 10% with Glycerine 10%); Dialysis and Irrigation Solution, such as Peritoneal Dialysis Solution with 1.7% Dextrose and 1.5% Glycine; Anti-infective and Anti-fungal, such as Ciprofloxacin 200mg and Metronidazole 500mg and others , such as Tamolgan (Paracetamol 1000mg) and PD-Invert (10% Invert Sugar). Its Oncology product mix includes 5 FU-PAR and BAZIPAR. Its Anesthesia product mix includes Sevoplan (Sevoflurane 100/250ml) and Isoplan (Isoflurane 100/250ml).
- Revenue in INR (TTM)84.96m
- Net income in INR-763.62m
- Incorporated1983
- Employees--
- LocationParenteral Drugs (India) LtdShree Ganesh ChambersNavlakha Crossing,, A. B. RoadINDORE 452001IndiaIND
- Phone+91 7 314092000
- Fax+91 7 312401052
- Websitehttp://www.pdindia.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Celestial Biolabs Limited | -100.00bn | -100.00bn | 44.23m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.8514 | -- | -0.9435 | -- | 37.11 | -- | -344.64 | -- | -- | -- | -- | -- | -67.83 | -- | -- | -- | -- |
| Parenteral Drugs (India) Ltd | 84.96m | -763.62m | 86.47m | -- | -- | -- | -- | 1.02 | -25.61 | -25.61 | 2.85 | -276.37 | 0.0162 | 4.17 | 0.9266 | -- | -14.52 | -17.82 | -- | -- | 35.67 | 40.22 | -898.77 | -191.93 | 0.055 | -0.5192 | -- | -- | -30.17 | -48.70 | 37.26 | -- | -- | -- |
| Ortin Laboratories Ltd | 34.23m | -41.00m | 146.77m | -- | -- | -- | -- | 4.29 | -5.02 | -5.02 | 4.10 | -- | -- | -- | -- | -- | -- | 0.376 | -- | 1.01 | -30.46 | 22.23 | -119.76 | 0.3017 | -- | -6.87 | -- | -- | -26.86 | -40.48 | 76.53 | -- | -- | -- |
